NASDAQ: ADILAdial Pharmaceuticals Inc Stock
$0.35-0.01 (-2.78%)
Updated Oct 31, 2025
ADIL Price
$0.35
Fair Value Price
$0.20
Market Cap
$7.64M
52 Week Low
$0.22
52 Week High
$1.30
P/E
-0.33x
P/B
1.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.45M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$6M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADIL Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADIL's potential to beat the market
- ADIL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADIL
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important ADIL news, forecast changes, insider trades & much more!
ADIL News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADIL ($0.35) is overvalued by 73.47% relative to our estimate of its Fair Value price of $0.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ADIL ($0.35) is not significantly undervalued (73.47%) relative to our estimate of its Fair Value price of $0.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADIL due diligence checks available for Premium users.
Valuation
ADIL fair value
Fair Value of ADIL stock based on Discounted Cash Flow (DCF)
Price
$0.35
Fair Value
$0.20
Overvalued by
73.47%
ADIL ($0.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADIL ($0.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
-9.17x
Market
41.55x
ADIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
4.99x
ADIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADIL's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
ADIL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.8M
Liabilities
$1.2M
Debt to equity
0.22
ADIL's short-term assets ($6.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADIL's short-term assets ($6.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADIL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$0.0
Financing
$5.3M
ADIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADIL vs Biotech Stocks
Adial Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.